Asterias Biotherapeutics Inc. Series A
AST
AST was delisted on the 7th of March, 2019.
62 hedge funds and large institutions have $13.3M invested in Asterias Biotherapeutics Inc. Series A in 2018 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 22 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less funds holding
Funds holding: 72 → 62 (-10)
16% less capital invested
Capital invested by funds: $15.9M → $13.3M (-$2.58M)
45% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 22
93% less call options, than puts
Call options by funds: $10K | Put options by funds: $148K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$752K |
| 2 |
ECM
Element Capital Management
New York
|
+$228K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$220K |
| 4 |
Renaissance Technologies
New York
|
+$161K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
+$125K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.69M |
| 2 |
State Street
Boston,
Massachusetts
|
-$525K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$389K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$133K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$121K |
AST Hedge Fund Activity: Q2 2018 in Review
62 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q2 2018, worth a combined $13.3M — down 16% from $15.9M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of AST and 12 opened new positions — a net loss of 10 holders — while 11 trimmed existing stakes and 14 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $752K. The largest seller was BlackRock, cutting an estimated $1.69M.
- 62 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q2 2018, down from 72 in Q1 2018.
- Funds reported $13.3M of Asterias Biotherapeutics Inc. Series A stock for Q2 2018, down 16% quarter-over-quarter.
- 12 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q2 2018 and 22 closed out, a net change of -10 holders.
- The largest Asterias Biotherapeutics Inc. Series A buyer in Q2 2018 was Millennium Management, an estimated $752K added.
- The largest Asterias Biotherapeutics Inc. Series A seller in Q2 2018 was BlackRock, an estimated $1.69M sold.
Based on aggregated 13F filings for Q2 2018.